Format
Sort by

Send to

Choose Destination

Search results

Items: 4

1.

Autologous Hematopoietic Cell Transplantation in Multiple Sclerosis: Changing Paradigms in the Era of Novel Agents.

Gavriilaki M, Sakellari I, Gavriilaki E, Kimiskidis VK, Anagnostopoulos A.

Stem Cells Int. 2019 Jun 24;2019:5840286. doi: 10.1155/2019/5840286. eCollection 2019. Review.

2.

Isolated Extramedullary Relapse as a Poor Predictor of Survival after Allogeneic Hematopoietic Cell Transplantation for Acute Leukemia.

Sakellari I, Gavriilaki E, Batsis I, Mallouri D, Gavriilaki M, Apostolou C, Iskas M, Voutiadou G, Bouziana S, Bousiou Z, Constantinou V, Masmanidou M, Sotiropoulos D, Yannaki E, Lalayanni C, Pilavaki M, Chatziioannou K, Papayannopoulos S, Anagnostopoulos A.

Biol Blood Marrow Transplant. 2019 May 22. pii: S1083-8791(19)30329-5. doi: 10.1016/j.bbmt.2019.05.018. [Epub ahead of print]

PMID:
31128329
3.

Neurological adverse events post allogeneic hematopoietic cell transplantation: major determinants of morbidity and mortality.

Sakellari I, Gavriilaki E, Papagiannopoulos S, Gavriilaki M, Batsis I, Mallouri D, Vardi A, Constantinou V, Masmanidou M, Yannaki E, Smias C, Geroukis T, Kazis D, Kimiskidis V, Anagnostopoulos A.

J Neurol. 2019 Aug;266(8):1960-1972. doi: 10.1007/s00415-019-09372-3. Epub 2019 May 13.

PMID:
31087160
4.

Reader response: Usefulness of ADAMTS13 to predict response to recanalization therapies in acute ischemic stroke.

Gavriilaki M, Sakellari I, Kimiskidis V.

Neurology. 2018 Nov 6;91(19):898-899. doi: 10.1212/WNL.0000000000006464. No abstract available.

PMID:
30397045

Supplemental Content

Loading ...
Support Center